甲氨蝶呤治疗类风湿关节炎：一项针对以色列患者的免疫遗传学相关性前瞻性研究。
Methotrexate in rheumatoid arthritis: a prospective study in Israeli patients with immunogenetic correlations.
作者信息
Tishler M, Caspi D, Rosenbach T O, Fishel B, Wigler I, Segal R, Gazit E, Yaron M
机构信息
Department of Rheumatology, Ichilov Hospital, Tel Aviv, Israel.
出版信息
Ann Rheum Dis. 1988 Aug;47(8):654-9. doi: 10.1136/ard.47.8.654.
In a prospective open study 44 Israeli patients with rheumatoid arthritis were treated with weekly low dose methotrexate (MTX) for up to 36 months. Nine patients withdrew from the study: six because of side effects and three due to inefficacy. One patient died of septicaemia following septic arthritis. Significant improvement, graded by Ritchie articular index, grip strength, physician's global assessment, erythrocyte sedimentation rate (ESR), and platelet counts, was noticed in response to treatment. Seronegative patients had a better clinical response. Transient gastrointestinal symptoms were common and correlated with increases of serum aspartate transaminase (AST). HLA-DR1 and DR7 were significantly associated with increased serum AST concentrations.
在一项前瞻性开放性研究中，44名以色列类风湿性关节炎患者接受了每周低剂量甲氨蝶呤（MTX）治疗，为期36个月。9名患者退出研究：6名因副作用，3名因无效。1名患者在感染性关节炎后死于败血症。根据里奇关节指数、握力、医生整体评估、红细胞沉降率（ESR）和血小板计数分级，治疗后有显著改善。血清阴性患者有更好的临床反应。短暂的胃肠道症状很常见，且与血清天冬氨酸转氨酶（AST）升高相关。HLA - DR1和DR7与血清AST浓度升高显著相关。
Zotero 插件